<DOC>
	<DOCNO>NCT00112593</DOCNO>
	<brief_summary>This clinical trial study side effect best dose give fludarabine total-body irradiation ( TBI ) together follow donor stem cell transplant cyclosporine mycophenolate mofetil treat human immunodeficiency virus ( HIV ) -positive patient without cancer . Giving low dos chemotherapy , fludarabine , TBI donor bone marrow peripheral blood stem cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine ( CSP ) mycophenolate mofetil ( MMF ) transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Total-Body Irradiation Followed By Donor Stem Cell Transplant Cyclosporine Mycophenolate Mofetil Treating HIV-Positive Patients With Without Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety treat high-risk HIV1-infected patient 200 centigray ( cGy ) TBI plus post-transplant MMF/CSP . II . To determine whether 200 cGy TBI plus post-transplant MMF/CSP result stable mixed donor lymphocyte chimerism ( 5-95 % donor cluster differentiation [ CD ] 3 ) high-risk human immunodeficiency virus ( HIV ) -1 infected patient . SECONDARY OBJECTIVES : I . To define kinetics immune reconstitution follow non-lethal condition regimen HIV1-infected patient . II . To determine effect non-lethal conditioning regimen viral load . OUTLINE : CONDITIONING REGIMEN : Patients receive fludarabine intravenously ( IV ) 2 hour day -4 , -3 , -2 . Patients undergo TBI day 0 . TRANSPLANTATION : After completion TBI , patient undergo allogeneic bone marrow peripheral blood stem cell transplantation day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine IV orally ( PO ) 2 3 time daily day -3 99 taper begin day 100 continue day 177 absence graft-vs-host disease ( GVHD ) . Beginning within 6 hour transplantation , patient also receive mycophenolate mofetil IV PO 3 time daily day 0 40 follow taper absence GVHD . After completion study treatment , patient follow least 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Leukemia , Mast-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients hematologic malignancy , lymphoma HIVassociated malignancy eligible provide criterion meet : The malignancy complete remission good partial remission , define significant reduction disease therapy evidence continue tumor growth case lymphoma solid tumor Highly active antiretroviral therapy ( HAART ) initiate within one month hematopoietic cell transplant Viral load decrease &gt; = 1.5 log viral load &lt; 5000 copies/ml plasma HAART therapy CD4 count allow &gt; 100 cells/ul HIV infect patient without malignancy fail HAART eligible provide criterion meet : They treat one regimen HAART total least 6 month duration The viral load &lt; 50 copies/ml plasma The CD4 count &lt; 100 cells/ul DONOR : Human leukocyte antigen ( HLA ) genotypically/phenotypically identical donor ; one HLAidentical sibling available , priority give donor match cytomegalovirus ( CMV ) status , ABO titer , sex Peripheral blood stem cell collect donor great 12 year age Bone marrow collect donor le 12 year age DONOR : HLA phenotypically identical unrelated donor ; match grade allow : Match grade 1 : Matched allele level HLAA , B , C , DRB1 , DQB1 Match grade 2.1 : Single allele disparity HLAA , B , C , DRB1 , DQB1 Positive serology toxoplasma gondii treatment evidence active infection Patients disease organ dysfunction would limit survival less 30 day Patients medical history noncompliance HAART medical therapy DONOR : Donors medical psychologic reason would make donor procedure intolerable DONOR : Marrow donor increase anesthetic risk DONOR : Donors HIV positive DONOR : Age &gt; 75 year</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
</DOC>